Peptides, blocked either at the N or C terminus, and thus unsuited for Edman degradation, and those containing N-alkylated amino acids, which are not detectable when using conventional amino acid analysis, can be easily sequenced by applying a method in which fast atom bombardment (FAB) is combined with tandem mass spectrometry (MSMS). Moreover, the structure of the N-alkylated amino acid constituents is provided by this approach. A widely applicable strategy will be presented, and to demonstrate its scope and limitations eighteen analogues of sequences related to the C terminus of substance P, a biologically active neuropeptide, were investigated. The power and reliability of the approach will be demonstrated by analyzing an 'unknown' peptide. Moreover, the detection and structure elucidation of N-alkylated amino acids which usually escape amino acid analysis will be described, as will be the unequivocal differentiation and identification of isomeric MeLeu/ MeIle. The influence of the N-alkylation on the mass spectrometric fragmentation behaviour will be discussed. Furthermore, the sequencing of two adipokinetic hormones by using the combined FAB-MSMS approach is described. Analysis of peptides can be achieved with sample sizes less than 0.1 pmol and be completed within 2-4 h Over the last few years an increasing number of naturally occurring, biologically active peptides was isolated, the sequencing of which was often seriously hampered by the fact that direct application of the Edman degradation was prevented by the presence of a blocked N terminus. Among the many N-protecting groups the N-pyroglutamic acid residue seems to play a pivotal role among the neuropeptide analogues. Furthermore, these peptide analogues often include several types of backbone modifications, among which replacements of various elements, namely the a-carbon, the amide NH group and/or the amide carbonyl, are known [I]. These peptides, in the present context termed modified peptides, were prepared for various reasons such as: a) to confer resistance towards enzymatic degradation which will result in metabolic stability; b) to alter rigidity or flexibility manifested in the normal peptide backbone in order to achieve more potent agonists or change them into antagonists; c) to change chemical and physical properties to effect the pharmacokinetics ; d) to study if the exact alignment and stereochemistry of the peptide backbone are critical for the resulting biologically function;